Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul>
<li>NetraMark expects its insights potentially could protect millions of R&amp;D dollars, increase drug development success rates, lower costs for drug sponsors &amp; shorten the time to commercialization of new therapies.</li>
<li>Developing &amp; commercializing a new drug takes an avg 10-15 years &amp; costs an avg $2.6B, while failure rates are nearly 90%.</li>
<li>In April 2025, NetraMark entered into a global agreement with CRO Worldwide Clinical Trials &amp; expects additional partnerships with other CROs &amp; pharma companies.</li>
</ul>


NetraMark expects its insights potentially could protect millions of R&amp;D dollars, increase drug development success rates, lower costs for drug sponsors &amp; shorten the time to commercialization of new therapies.
Developing &amp; commercializing a new drug takes an avg 10-15 years &amp; costs an avg $2.6B, while failure rates are nearly 90%.
In April 2025, NetraMark entered into a global agreement with CRO Worldwide Clinical Trials &amp; expects additional partnerships with other CROs &amp; pharma companies.


NetraMark Holdings Inc - Solutions to De-Risk Clinical Research Trials...